The Latest Cardiac and Vascular News
VANCOUVER, Sept. 30, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ (“Tiara”) transcatheter mitral valve replacement […]
SAN FRANCISCO, Sept. 29, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced new data demonstrating early and sustained health status advantages for severe aortic stenosis (AS) patients at low surgical risk treated with the Edwards SAPIEN 3 valve. […]
MAPLE GROVE, Minn., Sept. 30, 2019 /PRNewswire/ — 4C Medical Technologies, Inc., the creator of a new generation of therapies for structural heart disease, announced today that its medical device therapy for mitral regurgitation (MR), AltaValve™, was featured at Transcatheter Cardiovascular Therapeutics (TCT) 2019, on Sept 25-29 in San Francisco, CA. The AltaValve is a Transcatheter […]
Double-blind, randomized trial data demonstrates clinically meaningful and statistically significant difference of 8.1 mmHg in reduction of 24-hour ambulatory systolic blood pressure at 6 months vs. control High responder rate despite 88.5% of treated patients having isolated systolic hypertension (ISH) Primary safety endpoint achieved with no difference in major cardiac […]
Los Angeles, CA, Sept. 30, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”) today announces it has appointed Dr. William Li as Strategic Advisor to the CEO. Dr. Li and Endonovo CEO Alan Collier will work collaboratively and strategically to explore growth strategies for Endonovo’s […]
BETonMACE did not meet the primary endpoint Apabetalone development to continue to be advanced by the Company based on BETonMACE results Primary results to be presented during a late-breaking science session at AHA 2019 Apabetalone demonstrated tolerability and safety Resverlogix to host investor webcast and conference call on Monday, September […]
Nearly 80% of randomized patients have completed the studies Data clean-up for TRILOGY 1 is 90% completed Plan to present full data set including results for key secondary and exploratory endpoints of interest such as non-HDL-C, LDL-C, VLDL, HDL-C and HbA1c at key scientific meetings in 2020 […]
Growing Body of Evidence Supporting Use of the Tack Endovascular System® to Improve Balloon Angioplasty Outcomes for Patients Suffering from PAD WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the positive one-year results of its Tack Optimized Balloon Angioplasty (TOBA) III clinical trial, successfully achieving […]
During a heart attack, cardiologists say “time is muscle.” The time between when you arrive at the hospital and when your blockage is opened matters. The American Heart Association recommends a “door-to-balloon time” (D2B) of no more than 90 minutes. University Hospitals Portage Medical Center in Ravenna, Ohio blew that […]
New Study Shows Momentum in Establishing a Less Invasive Approach to Treat Patients with Severe Mitral Valve Disease DUBLIN, Sept. 27, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval to begin an early feasibility study (EFS) for its Intrepid™ transcatheter mitral […]
